Physician profile
Bindusagar H Reddy
NPI 1407886799
$5,008.69
in general payments reported to CMS, 2019-2025
28 companies · $618 in 2025
The $618 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $439 · 2021: $772 · 2022: $459 · 2023: $405 · 2024: $1,631 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,725 · Travel and Lodging: $910 · Education: $18.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,725.45 |
| Travel and Lodging | $910.11 |
| Education | $18.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $1,571.75 | 2024-2025 | Indigo System, Penumbra System |
| Abbott Laboratories | $715.95 | 2019-2025 | Gallant, Xience Skypoint, Jot Dx |
| Astrazeneca Pharmaceuticals LP | $296.69 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $281.65 | 2022-2025 | |
| Boston Scientific Corporation | $222.55 | 2019-2025 | Sq-Rx Pulse Generator, Latitude Communicator Power Supply, Mylux Patient Kit With Mobile Device |
| Vifor Pharma, INC. | $200.00 | 2021 | |
| Astellas Pharma US INC | $198.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.43 | 2021-2025 | Jardiance |
| Shockwave Medical, INC | $176.24 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $138.93 | 2019-2025 | |
| Novo Nordisk INC | $129.79 | 2021 | |
| Medtronic, INC. | $124.57 | 2023 | Contour 3d |
| Edwards Lifesciences Corporation | $119.19 | 2019 | |
| Lilly USA, LLC | $116.38 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $85.45 | 2019-2023 | Xarelto |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $65.37 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $60.34 | 2022-2025 | Eliquis, Camzyos |
| Amgen INC. | $54.82 | 2020-2021 | |
| Philips North America LLC | $50.22 | 2021 | |
| Bard Peripheral Vascular, INC. | $44.43 | 2024-2025 | Lifestream |
| Pfizer INC. | $31.60 | 2019-2023 | |
| Biotronik INC. | $21.95 | 2025 | Pk Papyrus |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Allergan, INC. | $21.33 | 2019 | |
| Chiesi USA, INC. | $21.00 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $20.17 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $15.65 | 2021 | |
| Braemar Manufacturing, LLC | $15.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bindusagar Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.